RE:RE:RE:Undervalued stockSunvalley, agreed that every big pharma would like to buy a smaller company outright, rather than in partnership. However, please keep in mind, this is not just any small company. TLT has the "rights" to develop this PDT 1433. PDT has been proven at different levels to increase the survival rate and or cure NMIBC completely. This is nothing short of Phenomenal success. In addition this company has the Fast Track designation from FDA which is granted only if FDA believes that PDT 1433 has an effective solution to treat or cure Blader Cancer that is not responsive to BCG. On top of all that the pivotal Phase 2 clinical study results are equally encouraging and FDA is likely to grant Theralase Technology BTD.
Break through Designation clearly indicates that FDA wants to bring this therapy to the commercial stage within the shortest time possible!!! Surely if TLD 1433 is granted BTD, the value of this stock is going to sky rocket. keeping in mind, when BTD is granted which according to their time line mid 2022, there will not be just ONE big pharma reaching out to TLT. I expect there would be multiple big pharma companies with joint venture proposals.. Big pharma companies are going to be competing with one another to develop this therapy and bring it to commercial stage. They simply do not have a choice!!
The current Management of Theralase has worked very hard for several years and will never Under sell this TLD to big pharma. I truly believe that there will be a very favourable stock offer from the Big pharma company, especially since TLT is still a micro cap company, compared to big pharma companies. Also keep in mind the current Management has a substantial stake in the company!!!. It is in their interest to negotiate for a lucrative stock offer if not a joint venture with Royalties for a decade!!